OXFORD, Ohio and DENVER, Colo., Sept. 7, 2022 /CNW/ – PsyBio Therapeutics Corp. ( TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions…


Previous articlePT353 – Dr. James Fadiman, Dr. Sam Gandy, & Dr. David Luke – Psychedelics and Creativity
Next articleatai Life Sciences to Participate in September Investor Events